Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer
Nab-Paclitaxel plus Gemcitabine and FOLFOXThis randomized, open-label, phase II trial compared nab-paclitaxel/gemcitabine followed by modified FOLFOX versus nab-paclitaxel/gemcitabine alone for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. Patients receiving nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) had a 12-month and 24-month overall survival of 55.3% and 22.4%, respectively, compared with 35.4% and 7.6% in the control group; there was a higher incidence of grade 3 or higher neutropenia and thrombocytopenia. No significant differences in febrile neutropenia, epistaxis or hemorrhage of grade 3 or higher in either group were reported. Two toxic deaths (2.6%) occurred in the experimental group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
NEJM evidence - 3(2024), 2 vom: 01. Feb., Seite EVIDoa2300144 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carrato, Alfredo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0W860991D6 |
|---|
| Anmerkungen: |
Date Completed 10.02.2024 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1056/EVIDoa2300144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368098699 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368098699 | ||
| 003 | DE-627 | ||
| 005 | 20240211232016.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/EVIDoa2300144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM368098699 | ||
| 035 | |a (NLM)38320486 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carrato, Alfredo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Nab-Paclitaxel plus Gemcitabine and FOLFOXThis randomized, open-label, phase II trial compared nab-paclitaxel/gemcitabine followed by modified FOLFOX versus nab-paclitaxel/gemcitabine alone for the first-line treatment of metastatic pancreatic ductal adenocarcinoma. Patients receiving nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) had a 12-month and 24-month overall survival of 55.3% and 22.4%, respectively, compared with 35.4% and 7.6% in the control group; there was a higher incidence of grade 3 or higher neutropenia and thrombocytopenia. No significant differences in febrile neutropenia, epistaxis or hemorrhage of grade 3 or higher in either group were reported. Two toxic deaths (2.6%) occurred in the experimental group | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a 130-nm albumin-bound paclitaxel |2 NLM | |
| 650 | 7 | |a Albumins |2 NLM | |
| 650 | 7 | |a Deoxycytidine |2 NLM | |
| 650 | 7 | |a 0W860991D6 |2 NLM | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 650 | 7 | |a Paclitaxel |2 NLM | |
| 650 | 7 | |a P88XT4IS4D |2 NLM | |
| 700 | 1 | |a Pazo-Cid, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Macarulla, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Fonseca, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Cano, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Garrote, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Pericay, Carles |e verfasserin |4 aut | |
| 700 | 1 | |a Alés, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Layos, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Graña, Begoña |e verfasserin |4 aut | |
| 700 | 1 | |a Iranzo, Vega |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Carbonero, Rocio |e verfasserin |4 aut | |
| 700 | 1 | |a de Mena, Inmaculada Ruiz |e verfasserin |4 aut | |
| 700 | 1 | |a Guillén-Ponce, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Aranda, Enrique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NEJM evidence |d 2022 |g 3(2024), 2 vom: 01. Feb., Seite EVIDoa2300144 |w (DE-627)NLM339641495 |x 2766-5526 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:EVIDoa2300144 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/EVIDoa2300144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2024 |e 2 |b 01 |c 02 |h EVIDoa2300144 | ||